ES2639039T3 - Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico - Google Patents
Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico Download PDFInfo
- Publication number
- ES2639039T3 ES2639039T3 ES11796846.1T ES11796846T ES2639039T3 ES 2639039 T3 ES2639039 T3 ES 2639039T3 ES 11796846 T ES11796846 T ES 11796846T ES 2639039 T3 ES2639039 T3 ES 2639039T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acids
- fviii1401
- amino acid
- fviii246
- fviii102
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 142
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 title description 93
- 102100026735 Coagulation factor VIII Human genes 0.000 title description 88
- 102000004196 processed proteins & peptides Human genes 0.000 title description 45
- 230000006058 immune tolerance Effects 0.000 title description 2
- 230000006698 induction Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract description 308
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 235000001014 amino acid Nutrition 0.000 description 176
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 108010054218 Factor VIII Proteins 0.000 description 6
- 102000001690 Factor VIII Human genes 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 229960000301 factor viii Drugs 0.000 description 5
- 102000057593 human F8 Human genes 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 241001146702 Candidatus Entotheonella factor Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000521327 Streptomyces caespitosus Species 0.000 description 1
- 208000013633 acquired hemophilia Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40740210P | 2010-10-27 | 2010-10-27 | |
| US407402P | 2010-10-27 | ||
| US201161467894P | 2011-03-25 | 2011-03-25 | |
| US201161467894P | 2011-03-25 | ||
| US201161502476P | 2011-06-29 | 2011-06-29 | |
| US201161502476P | 2011-06-29 | ||
| PCT/US2011/058165 WO2012058480A1 (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2639039T3 true ES2639039T3 (es) | 2017-10-25 |
Family
ID=45349271
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11796846.1T Active ES2639039T3 (es) | 2010-10-27 | 2011-10-27 | Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico |
| ES17167928T Active ES2912455T3 (es) | 2010-10-27 | 2011-10-27 | Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17167928T Active ES2912455T3 (es) | 2010-10-27 | 2011-10-27 | Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8969524B2 (enExample) |
| EP (2) | EP3260132B1 (enExample) |
| JP (2) | JP6122780B2 (enExample) |
| KR (2) | KR102040867B1 (enExample) |
| CN (2) | CN104926947A (enExample) |
| AR (1) | AR083586A1 (enExample) |
| AU (2) | AU2011319747C1 (enExample) |
| BR (1) | BR112013010362A2 (enExample) |
| CA (1) | CA2815239C (enExample) |
| DK (1) | DK2632479T3 (enExample) |
| EA (1) | EA034494B1 (enExample) |
| ES (2) | ES2639039T3 (enExample) |
| HK (1) | HK1215442A1 (enExample) |
| MX (1) | MX347805B (enExample) |
| NZ (2) | NZ609474A (enExample) |
| PL (2) | PL3260132T3 (enExample) |
| PT (1) | PT2632479T (enExample) |
| SG (2) | SG10201600656WA (enExample) |
| TW (3) | TW201708251A (enExample) |
| WO (1) | WO2012058480A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100256062A1 (en) | 2004-12-06 | 2010-10-07 | Howard Tommy E | Allelic Variants of Human Factor VIII |
| AU2013343024B2 (en) * | 2012-11-12 | 2017-06-01 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | Peptides |
| WO2014089541A2 (en) | 2012-12-07 | 2014-06-12 | Haplomics, Inc. | Factor viii mutation repair and tolerance induction |
| US20160038575A1 (en) * | 2013-03-15 | 2016-02-11 | Haplomics, Inc. | Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a |
| WO2017180807A1 (en) | 2016-04-15 | 2017-10-19 | Baxalta Incorporated | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
| CA2951150C (en) * | 2014-06-12 | 2024-05-28 | University Of Hawaii | Uses of humanized cobra venom factor for reducing or preventing immunogenicity |
| JP2018504145A (ja) * | 2015-01-26 | 2018-02-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞 |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040103970A (ko) * | 2002-04-18 | 2004-12-09 | 메르크 파텐트 게엠베하 | 변형된 펙터 ⅷ |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| EP1766412B1 (en) * | 2004-05-21 | 2009-04-01 | The Institute for Systems Biology | Compositions and methods for quantification of serum glycoproteins |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| CA2633306A1 (en) | 2006-01-04 | 2007-07-12 | Baxter International Inc. | Oligopeptide-free cell culture media |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| US7673687B2 (en) | 2007-12-05 | 2010-03-09 | Halliburton Energy Services, Inc. | Cement compositions comprising crystalline organic materials and methods of using same |
| DE202007017320U1 (de) | 2007-12-07 | 2008-02-28 | Dittmann, Ludwig | Vorrichtung zur Raumbeduftung |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| WO2009099991A2 (en) | 2008-01-31 | 2009-08-13 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US20100168018A1 (en) | 2008-11-07 | 2010-07-01 | Baxter International Inc. | Factor viii formulations |
-
2011
- 2011-10-27 SG SG10201600656WA patent/SG10201600656WA/en unknown
- 2011-10-27 MX MX2013004753A patent/MX347805B/es active IP Right Grant
- 2011-10-27 ES ES11796846.1T patent/ES2639039T3/es active Active
- 2011-10-27 SG SG2013028733A patent/SG189914A1/en unknown
- 2011-10-27 KR KR1020137013231A patent/KR102040867B1/ko active Active
- 2011-10-27 US US13/283,452 patent/US8969524B2/en active Active
- 2011-10-27 EA EA201390617A patent/EA034494B1/ru not_active IP Right Cessation
- 2011-10-27 CN CN201510431485.4A patent/CN104926947A/zh active Pending
- 2011-10-27 ES ES17167928T patent/ES2912455T3/es active Active
- 2011-10-27 TW TW105138248A patent/TW201708251A/zh unknown
- 2011-10-27 CN CN201180063117.9A patent/CN103298482B/zh active Active
- 2011-10-27 EP EP17167928.5A patent/EP3260132B1/en active Active
- 2011-10-27 TW TW106113613A patent/TW201730205A/zh unknown
- 2011-10-27 KR KR1020197032106A patent/KR102222864B1/ko not_active Expired - Fee Related
- 2011-10-27 NZ NZ609474A patent/NZ609474A/en unknown
- 2011-10-27 PL PL17167928.5T patent/PL3260132T3/pl unknown
- 2011-10-27 PT PT117968461T patent/PT2632479T/pt unknown
- 2011-10-27 TW TW100139078A patent/TWI580430B/zh active
- 2011-10-27 CA CA2815239A patent/CA2815239C/en active Active
- 2011-10-27 AU AU2011319747A patent/AU2011319747C1/en active Active
- 2011-10-27 PL PL11796846T patent/PL2632479T3/pl unknown
- 2011-10-27 DK DK11796846.1T patent/DK2632479T3/en active
- 2011-10-27 NZ NZ703514A patent/NZ703514A/en unknown
- 2011-10-27 WO PCT/US2011/058165 patent/WO2012058480A1/en not_active Ceased
- 2011-10-27 JP JP2013536845A patent/JP6122780B2/ja not_active Expired - Fee Related
- 2011-10-27 BR BR112013010362A patent/BR112013010362A2/pt not_active Application Discontinuation
- 2011-10-27 EP EP11796846.1A patent/EP2632479B1/en active Active
- 2011-10-28 AR ARP110103988A patent/AR083586A1/es not_active Application Discontinuation
-
2015
- 2015-01-23 US US14/604,622 patent/US9512198B2/en active Active
-
2016
- 2016-03-22 HK HK16103339.6A patent/HK1215442A1/zh unknown
- 2016-04-06 AU AU2016202155A patent/AU2016202155B2/en active Active
- 2016-11-02 US US15/341,936 patent/US20170267743A1/en not_active Abandoned
- 2016-11-29 JP JP2016230723A patent/JP2017095463A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2639039T3 (es) | Péptidos de FVIII para la inducción de tolerancia inmunitaria e inmunodiagnóstico | |
| US20230192767A1 (en) | Il-2rgamma binding compounds | |
| JP7248247B2 (ja) | Ｗｔ１抗原ペプチドコンジュゲートワクチン | |
| DK2341142T3 (en) | HLA-A * 1101-restricted WT1 peptide or pharmaceutical composition comprising this | |
| US20250171501A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| US20150239932A1 (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| EA027040B1 (ru) | Модулирующие иммуносупрессию соединения | |
| ES2585246T3 (es) | Fibrinógeno recombinante | |
| UA129833C2 (uk) | Гібридний білок, що містить поліпептид варіантного ліганду icos | |
| JP2007530439A (ja) | エリスロポエチン受容体に結合する新規ペプチド | |
| Grundemar et al. | Activation of neuropeptide Y1 and neuropeptide Y2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes | |
| US20200062811A1 (en) | Yap protein inhibiting polypeptide and application thereof | |
| US10441628B2 (en) | High activity tumour inhibitor and preparation method and use thereof | |
| RU2013111675A (ru) | Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc | |
| ES2617062T3 (es) | Péptidos VEGF quiméricos | |
| JP7703541B2 (ja) | 血清アルブミン結合性フィブロネクチンｉｉｉ型ドメインおよびその使用 | |
| JP2019501964A (ja) | ポリペプチド化合物、並びにその調製方法及び適用 | |
| JPH02288899A (ja) | 成熟肝実質細胞増殖因子（ｉ） | |
| WO2011060018A2 (en) | Compositions and methods for using peptides, modified peptides, peptidomimetics and fibrin derivatives | |
| CN108084247B (zh) | 一种合成多肽及其合成方法和应用 | |
| PT98109A (pt) | Processo recombinante para a preparacao duma nova proteina | |
| JP2012082213A5 (enExample) | ||
| AU2012227350A1 (en) | HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same | |
| RU2008130395A (ru) | Вакцины и их применение |